HCC updates from ILCA and ESMO congressess 2022

Episode 1 October 06, 2022 00:30:22
HCC updates from ILCA and ESMO congressess 2022
COR2ED Medical Education
HCC updates from ILCA and ESMO congressess 2022

Oct 06 2022 | 00:30:22

/

Show Notes

COR2ED Medical Education: In this HCC CONNECT podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented and discussed at the ILCA and ESMO congresses. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discuss new treatment options in first line for advanced HCC presented at ESMO including the three late breaking abstracts LEAP-002, RATIONALE-301 and tislelizumab monotherapy trials. The latter two studying first-line treatment with an anti-PD1 antibody with or without a kinase inhibitor in patients with advanced hepatocellular carcinoma. The experts evaluate and provide their insights into how to integrate these new treatments for HCC in the clinical practice.

Other Episodes

Episode 2

October 03, 2021 00:16:30
Episode Cover

ASBMR 2021 Rare Bone Disease Highlights from Day Two

We have partnered with international experts to provide rare bone diseases highlights from ASBMR 2021. This is the second in a series of four...

Listen

Episode 4

October 19, 2021 00:30:42
Episode Cover

The use of VEGFR-TKIs monotherapy in the treatment of unresectable or advanced HCC in 1L setting

The use of VEGFR-TKIs monotherapy in the treatment of unresectable or advanced HCC in 1L setting: Who can benefit and guidance on implementation of...

Listen

Episode 14

June 28, 2023 00:30:45
Episode Cover

PBC Highlights from EASL 2023: Episode 1

COR2ED Medical Education: Prof. Gideon Hirschfield, Professor of Medicine, Division of Gastroenterology, University of Toronto, Canada and Dr Emma Culver, Consultant Hepatologist and Honorary...

Listen